Long-term follow-up results from the GLORY study: phase II study of gumarontinib in East Asian patients with MET exon 14 skipping mutated non-small cell lung cancer
Shun Lü(Shanghai Jiao Tong University), Yibin Wang(Data Management (Italy)), Diansheng Zhong(Tianjin Medical University General Hospital), Dingzhi Huang(Tianjin Medical University Cancer Institute and Hospital), Jun Sakakibara(University of Tsukuba), Kazumi Nishino(Osaka Medical Center for Cancer and Cardiovascular Diseases), Jiuwei Cui(Jilin University), Kōichi Goto(National Cancer Center Hospital East), Xingya Li(First Affiliated Hospital of Zhengzhou University), Li Lü(Tongji Hospital), Yanqiu Zhao(Henan Cancer Hospital), Yongqian Shu(Jiangsu Cancer Hospital), Chong Bai(Sun Yat-sen University), Lingnan Wu(Hunan Cancer Hospital), Jian Fang(Soochow University), Aimin Zang(Affiliated Hospital of Hebei University), Yiping Zhang(Zhejiang Cancer Hospital), Yan Yu(Army Medical University), Xiaoling Li(First Affiliated Hospital of Zhengzhou University), Wei Zhang(Nanchang University), Li Zhang(Centre international de recherche sur le cancer), Meiqi Shi(Jiangsu Cancer Hospital), Xiaorong Dong(Union Hospital), Xuhong Min(Xi'an Chest Hospital), Chengzhi Zhou(First Affiliated Hospital of Guangzhou Medical University), Yongfeng Yu(Shanghai Chest Hospital), Lejie Cao(University of Science and Technology of China), Yasuto Yoneshima(Kyushu University Hospital), Fugen Li(Precision for Medicine (United States)), Wenhao Duanmu(Jiangsu T-mab BioPharma (China)), Jianya Zhou(First Affiliated Hospital Zhejiang University)
Cited by 2
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|1.7k
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
|The Lancet Oncology|2015|1.6k
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
|The Lancet Oncology|2016|1.2k
Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy
|Signal Transduction and Targeted Therapy|2022|988